Roche Successfully Acquires Sarepta License in $1.15 Billion Deal

Roche Holding made its second main gene therapy agreement in a year on Monday, spending $1.15 billion to acquire the rights to Sarepta Therapeutics’s investigational drug to treat Duchenne muscular Dystrophy (DMD) outside the U.S.

The Swiss drug company concluded a $4.3 billion offer to acquire Sparks Therapeutics this month, marking the growing appetite amongst large drug companies for gene therapies.

Roche will make an advance payment of $750 million in cash and take a $400 million stake in Sarepta, costing $158.59 per share, a premium of about 26% to the U.S. drugmaker’s closing value on Friday.

Shares of Sarepta, which already has non-gene therapies for DMD out there, were up 9% at $138 before the bell.

Gene therapies, one of the hottest sectors of drug analysis, aim to fix certain ailments by replacing the missing or mutated model of a gene found in a patient’s cells with good copies.

Earlier this month, Japan’s Astellas Pharma stated it was buying gene remedy developer Audentes Therapeutics for about $3 billion – over double the U.S. firm’s market value at the time.

DMD is a rare degenerative neuromuscular dysfunction, which impacts about one in 3,500-5,000 male births across the globe, causes severe progressive muscle loss and premature death.

Sarepta already has a significant presence in the DMD sector. Its Exondys 51, a non-gene remedy that was authorized in 2016, brought in sales of $99 million within the newest quarter.

Show More

Joseph Flowers

Joseph is leading the team writing under the medicine category. Before joining health dialysis, he has worked with many research organization and also in labs and hence his understandings on the field of medicine is vast and exciting. His articles hold the account for every recalled medication and even those medicines whose approval has risen a storm in the market. Personality wise he is a very soft-spoken person.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *